sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Lasmiditan

Lasmiditan

CAS No.:
439239-90-4
Catalog Number:
AG00DB6J
Molecular Formula:
C19H18F3N3O2
Molecular Weight:
377.3603
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG00DB6J
Chemical Name:
Lasmiditan
CAS Number:
439239-90-4
Molecular Formula:
C19H18F3N3O2
Molecular Weight:
377.3603
MDL Number:
MFCD18633238
IUPAC Name:
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
InChI:
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
InChI Key:
XEDHVZKDSYZQBF-UHFFFAOYSA-N
SMILES:
CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F
UNII:
760I9WM792
Properties
Complexity:
530  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
377.135g/mol
Formal Charge:
0
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
377.367g/mol
Monoisotopic Mass:
377.135g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
62.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.8  
Literature
Title Journal
Emerging treatment for chronic migraine and refractory chronic migraine. Expert opinion on emerging drugs 20120901
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. The journal of headache and pain 20120601
Defining and refining 5-HT receptor targets for migraine. The Lancet. Neurology 20120501
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. The Lancet. Neurology 20120501
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment. Cephalalgia : an international journal of headache 20110701
Treatment of migraine: update on new therapies. Current opinion in neurology 20110601
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia : an international journal of headache 20101001
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia : an international journal of headache 20101001
Molecule of the month. Lasmiditan hydrochloride. Drug news & perspectives 20100901
Properties